Described herein are compositions and methods for inhibition of Asialoglycoprotein receptor 1 (ASGR1) gene expression. RNA interference (RNAi) agents, e.g., double stranded RNAi agents, and RNAi agent-targeting ligand conjugates for inhibiting the expression of an ASGR1 gene are described. Pharmaceutical compositions comprising one or more ASGR1 RNAi agents, optionally with one or more additional therapeutics, are also described. The ASGR1 RNAi agents can be used in methods of treatment of various diseases and conditions, such as cardiometabolic diseases related to elevated non-HDL cholesterol (non-HDL-C) levels, elevated LDL cholesterol (LDL-C) levels, elevated total cholesterol levels, and/or elevated triglyceride (TG) levels.本文描述用於抑制去唾液酸醣蛋白受體1 (ASGR1)基因表現之組合物及方法。描述用於抑制ASGR1基因表現之RNA干擾(RNAi)試劑，例如雙鏈RNAi試劑及RNAi試劑-靶向配位體結合物。亦描述包含一或多種 ASGR1RNAi試劑之醫藥組合物，其視情況具有一或多種額外治療劑。該等 ASGR1RNAi試劑可用於各種疾病及病狀之治療方法中，該等疾病及病狀諸如與非HDL膽固醇(非HDL-C)含量提高、LDL膽固醇(LDL-C)含量提高、總膽固醇含量提高及/或三酸甘油酯(TG)含量提高相關之心血管代謝疾病。
